Sorry, you need to enable JavaScript to visit this website.



Improving Quality of Life While Searching for Treatments

Huntington’s disease (also known as Huntington's chorea) is a rare genetic disorder that usually affects middle-aged people. It destroys cells in the brain, affecting the ability to move, think, and behave. The disease gets worse over time, eventually rendering patients unable to live without assistance and leading to death. For those who carry the fatal gene, an important question they face is whether or not they are better off knowing that they have the disease, especially when there is no cure. Pfizer is working closely with healthcare professionals and patients to improve quality of life by developing new treatment options.

On this page, you'll find information on the condition, its diagnosis and treatment, our pipeline, as well as useful Pfizer resources.

Disease Education Information

Pfizer Rare Disease Resources

Pipeline and Clinical Trials
Pfizer's growing arsenal of rare disease treatments target diseases like Huntington's. More information is available on new drugs in our pipeline, as well as clinical trials of potential treatments.
Pfizer actively seeks partnerships with research institutes, universities, companies, patient advocacy organizations, and other groups to accelerate the availability of groundbreaking therapies that will make a real difference in the lives of patients suffering from Huntington's and other rare diseases.
Pfizer Rare Disease Consortium
Pfizer is focusing on collaborations with world-class R&D organizations to advance and speed rare disease treatment innovations. The Pfizer Rare Disease Consortium in the UK, our first center of excellence in rare disease research, is a model for future collaborations in Europe and the US.
Grants and Contributions
Pfizer offers grants and funding for research and programs designed to improve daily life and outcomes for patients with rare diseases.
Rare Disease Research
A deeper understanding of the genetics of rare diseases gives us an opportunity to explore breakthrough science, new approaches and pioneering collaborations to potentially deliver next-generation therapies for people living with rare diseases.